///Beaumont Study Seeks Women With IC/BPS (Royal Oak, MI)

Beaumont Study Seeks Women With IC/BPS (Royal Oak, MI)

Have you been diagnosed with IC/BPS?

If you are a female between the ages of 18 and 85, with urinary frequency, urgency and pelvic discomfort or pain for at least six months, you may be eligible to participate in a clinical research study. IC/BPS affects 15 to 24 percent of adult women and has a significant impact on quality of life.

The goal of this study is to compare the results of bladder directed therapy (bladder instillations) versus non-bladder physical therapy.

Study Information

The study is open to women between the ages of 18 and 85 who have been diagnosed with IC/BPS. The goal of this study is to evaluate the effectiveness of twice weekly bladder directed therapy (bladder instillations) in comparison to non-bladder therapy. Study participants are randomly assigned to treatment groups, meaning you cannot choose the treatment you receive. Randomization is like “the flip of a coin”.

Screening for eligibility initially involves a phone call. If initial eligibility criteria are met, you will be scheduled for two screening visits, which will include:

  • medical history
  • physical exam
  • pelvic floor assessment
  • pelvic floor EMG (electromyography)
  • cystoscopy
  • urinating/symptom diary
  • questionnaires

What is expected of me?

If you meet the criteria to be included in the study, you will be scheduled to have:

  • twice weekly treatment sessions for eight weeks
  • two follow up appointments
  • phone or mail monitoring every six months, up to five times after treatment completion

You will be assigned randomly to the bladder instillation (via urinary catheter) or non-bladder therapy group.

Any treatment will be at no cost to you, and there is no compensation for study participation.

Total expected study duration – up to three and a half years.

If you are interested in participating in this study, please contact one of our research nurse clinicians:
Urology Research at Beaumont Hospital, Royal Oak 248-551-3355

By |2018-05-07T21:03:52+00:00April 25th, 2018|Clinical Trials, Research|Comments Off on Beaumont Study Seeks Women With IC/BPS (Royal Oak, MI)

About the Author:

My Google Profile+ Jill Heidi Osborne is the president and founder of the Interstitial Cystitis Network, a health education company dedicated to interstitial cystitis, bladder pain syndrome and other pelvic pain disorders. As the editor and lead author of the ICN and the IC Optimist magazine, Jill is proud of the academic recognition that her website has achieved. The University of London rated the ICN as the top IC website for accuracy, credibility, readability and quality. (Int Urogynecol J - April 2013). Harvard Medical School rated both Medscape and the ICN as the top two websites dedicated to IC. (Urology - Sept 11). Jill currently serves on the Congressionally Directed Medical Research Panel (US Army) where she collaborates with researchers to evaluate new IC research studies for possible funding. Jill has conducted and/or collaborates on a variety of IC research studies on new therapeutics, pain care, sexuality, the use of medical marijuana, menopause and the cost of treatments, shining a light on issues that influence patient quality of life. An IC support group leader and national spokesperson for the past 20 years, she has represented the IC community on radio, TV shows, at medical conferences. She has written hundreds of articles on IC and its related conditions. With a Bachelors Degree in Pharmacology and a Masters in Psychology, Jill was named Presidential Management Intern (aka Fellowship) while in graduate school. (She was unable to earn her PhD due to the onset of her IC.) She spends the majority of her time providing WELLNESS COACHING for patients in need and developing new, internet based educational and support tools for IC patients, including the “Living with IC” video series currently on YouTube and the ICN Food List smartphone app! Jill was diagnosed with IC at the age of 32 but first showed symptoms at the age of 12.